J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
Johnson & Johnson (J&J) Innovation Medicine has submitted a request to the US Food and Drug Administration (FDA) to approve…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
-
-
Enveda raises $130m to advance AI-driven plant based drug development
Artificial Intelligence (AI)-driven biotech Enveda Biosciences has raised $130m in a Series C funding round to accelerate its drug discovery…
-
Samsung Biologics inks $668m manufacturing deal with European pharma
Samsung Biologics has announced another significant manufacturing agreement, securing a $668m contract with a Europe-based pharmaceutical company. This latest deal…
-
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies
Takeda and Alloy Therapeutics have announced a new partnership to accelerate the development of advanced cancer therapies using innovative stem…
-
UK life science startups have trouble “scaling up” says Lord Vallance
While the UK's life sciences and biotech sector has strong early-stage academic work, a thriving startup scene, and world-class universities,…
-
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
The UK’s National Institute for Health and Care Excellence (NICE) has once again rejected Daiichi Sankyo and AstraZeneca's breast cancer…
-
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy for Duchenne muscular…
-
Novartis strengthens radiopharma leadership with Ratio Therapeutics deal
Novartis is bolstering its leadership in the radiopharmaceutical space by partnering with US-based startup Ratio Therapeutics to develop a somatostatin…
-
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia Therapeutics has announced early-stage clinical data suggesting that its investigational gene editing treatment may stabilise or improve outcomes for…
-
AbbVie’s Elahere wins European approval for certain ovarian cancers
The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab soravtansine) for the treatment of folate receptor-alpha (FRα)…